Introduction
Real-World Evidence (RWE) is the lifeblood of modern clinical research and market access. However, utilizing this data requires navigating a labyrinth of global privacy regulations, cross-border data transfer restrictions, and stringent InfoSec mandates. In response, the industry has rapidly adopted synthetic data-artificially generated datasets that mimic the statistical properties of real patient populations without containing actual Protected Health Information (PHI).
While synthetic data presents a massive opportunity to accelerate research while maintaining patient confidentiality, it introduces complex new challenges for InfoSec and Data Compliance teams. If not rigorously governed, synthetic datasets can introduce “Zombie Data”-information with unknown provenance that degrades AI models and creates severe compliance liabilities. This blog explores the critical need for synthetic data governance and how InfoSec teams can safely enable RWE innovation.
The Growing Concern: "Zombie Data" and Provenance Risks
- Synthetic Data Creep: When fabricated or imputed records are mixed into licensed real-world datasets without clear disclosure, it creates "synthetic data creep." AI models trained on this impure data suffer from model collapse, reducing their predictive power. (HealthVerity)
- Data Provenance Failures: Many data resellers cannot trace the origins of their datasets. With increasing regulatory scrutiny on data lineage, utilizing datasets with fragmented identities or unknown origins leaves researchers exposed to compliance failures.
- Re-identification Vulnerabilities: High-fidelity synthetic data that too closely mirrors original outliers can still be vulnerable to linkage attacks, meaning privacy is not guaranteed by synthesis alone.
The Role of InfoSec in Synthetic Data Governance:
a) Enforcing Verifiable Data Provenance InfoSec and compliance teams must implement strict auditability frameworks. Every dataset ingested for RWE must have a clear, source-traceable lineage. By utilizing probabilistic identity resolution rather than legacy tokenization, organizations can ensure that fragmented patient identities are resolved without relying on imputed or “zombie” records.
b) Rigorous Privacy and Risk Evaluations Generating synthetic data is not a silver bullet for HIPAA or GDPR compliance. Compliance teams must mandate privacy evaluations, including “information gain analyses,” which mathematically quantify how much information about the original source data can be inferred from the synthetic dataset. This ensures re-identification risks remain below regulatory thresholds.
c) Integration with Secure Processing Environments (SPEs)Â As frameworks like the European Health Data Space (EHDS) mandate highly secure environments for the secondary use of health data, InfoSec must ensure that synthetic data generation and analysis occur within zero-trust Secure Processing Environments. Data should never be downloaded or transferred outside of these approved, monitored frameworks.
Market Trends and Future Outlook
- Market Expansion: The synthetic data governance platforms market is projected to grow from $1.74 billion in 2025 to $2.33 billion in 2026, expanding at a remarkable CAGR of 34.2%. (The Business Research Company)
- GenAI Integration: The broader Generative AI in healthcare market is accelerating past $2.26 billion in 2026, with synthetic data generation becoming a primary tool to bypass data scarcity and privacy bottlenecks. (John Snow Labs)
Regulatory Landscape and Compliance
- European Health Data Space (EHDS): Entering its application phase following its 2025 publication, the EHDS strictly governs the "secondary use" of health data (EHDS2). It mandates that data processing-including anonymization and synthesis-must occur in secure processing environments that comply with the highest EU cybersecurity standards.
- FDA & EMA Scrutiny: Regulatory bodies are increasingly scrutinizing the data lineage of RWE submitted for drug approvals, demanding transparent documentation of de-identification and synthesis techniques to ensure fit-for-purpose usability.
Conclusion
The integration of synthetic data into RWE pipelines is an unstoppable force, offering incredible benefits for privacy-preserving research. However, the unchecked proliferation of these datasets introduces severe risks to data integrity and regulatory compliance.
Looking ahead, the burden falls on Data Compliance and InfoSec leaders to establish robust synthetic data governance. By implementing verifiable data provenance, rigorous re-identification testing, and Secure Processing Environments, organizations can eliminate the threat of “Zombie Data.” In 2026 and beyond, trust in RWE will not just be about having the most data-it will be about having the most governed, secure, and verifiable data.
Insights That Drive Impact
Healthcare is evolving faster than ever — and those who adapt are the ones who will lead the change.
Stay ahead of the curve with our in-depth insights, expert perspectives, and a strategic lens on what’s next for the industry.
